One of the key launch points for the modern biotechnology industry was not in the Bay Area or San Diego or Cambridge, ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Perceive Pharma, a pharmaceutical company pioneering novel small molecule therapeutics in ophthalmology, today announced the closing of a $15M Series A funding round including Deerfield Management, ...

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...

Mama’s Kitchen is among the awardees who received a Direct Relief grant, which mobilizes financial resources for organizations ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Data from this study will be presented at the Crohn's and Colitis Congress (CCC), being held from February 6-8, 2025 in San Franci Eli Lilly and Company (NYSE: LLY) today announced its financial ...